ChargePoint Technology launches single-use technology as part of powder transfer solutions portfolio
Company's hybrid solution claims superior performance compared with tradition single-use technologies.
Contained and sterile transfer solutions expert, ChargePoint Technology has announced new, single-use additions to its portfolio - the ChargePoint Single Use Passive (SUP) and ChargeBag PE-S with new HiPure ULP7 PE film.
Together, the two products form a high performance, single-use package for the contained and sterile transfer of pharmaceutical powders between manufacturing process steps or even facilities.
The ChargePoint SUP is a disposable version of the passive mating half of the ChargePoint SBV (Split Butterfly Valve) technology, which forms a complete hybrid system to ensure users can take advantage of the benefits of disposable technology without compromising performance. This also ensures the new single-use products are compatible with existing ChargePoint SBV systems in the field.
Constructed completely of FDA and USP Class VI compliant materials, the SUP is both lightweight and cost effective, delivering containment and sterility assurance performance while eliminating the time and cost associated with cleaning, maintenance and validation.
The new ChargeBag PE-S is a flexible, single-use product container for the handling, storage and transfer of bio-pharmaceutical powders.
Manufactured from HiPure ULP7, a new proprietary film, developed exclusively by ChargePoint Technology, and compliance tested to meet the demands of even the most critical aseptic processing environments, the solution enables extremely high levels of integrity with optimised purity and robustness characteristics.
Chris Eccles, CEO, ChargePoint Technology says: “As pharmaceutical manufacturing environments evolve, we will continue to push the boundaries of innovation and remain at the forefront of contained transfer advancements, responding to the challenges of today and tomorrow. We are excited to take our first steps into the realm of single-use technology as we look for new ways to deliver compliant, flexible solutions to our customers.”
He continues: “Although traditional single-use technologies claim to deliver the same level of performance as some of the more robust solutions, the reality is this is not the case over repeated operations. ChargePoint’s hybrid solution delivers repeatable performance as well as offering several advantages to pharmaceutical manufacturers. The convenience and control benefits associated with pre-validated, ready to use solutions, that are easily integrated and perform to the highest level of containment and sterility assurance, are invaluable for our customers”.
In line with the next generation of transfer solutions, ChargePoint Technology is also introducing its latest update of the ChargePoint SBV system, Series 3. Featuring a new and improved locking mechanism with intuitive mechanical interlocks the system is operator friendly and reduces risk of part wear. On automatic versions, quick release actuators and sensor sockets ensure fast set up and changeover while improved access to the main disc seal makes maintenance steps more convenient than ever before.
Related News
-
News Women in Pharma: Moving beyond discussions and into best practice at CPHI Milan
In this second CPHI Milan special of our monthly series, we cover the key takeaways from the Diversity & Wellbeing track held on October 10, 2024. -
News AstraZeneca invests in AI collaboration for cancer drug trials
The British-Swedish pharmaceutical giant is partnering with biotechnology firm Immunai Inc to increase the efficiency of some cancer drug trials. -
News Ozempic and Wegovy prices questioned as Novo Nordisk faces US Senate hearing
The CEO of Novo Nordisk was grilled during a US Senate committee hearing on September 24, 2024, in which the exorbitant prices of the Danish company’s blockbuster drugs Ozempic and Wegovy were called into question. -
News The BIOSECURE Act: implications for the pharma supply chain
On September 9, 2024, the US House of Representatives voted to pass the bill titled the BIOSECURE Act (the Act), which lists several Chinese companies in the pharmaceutical supply chain. The Act will prohibit American companies from contracting or doin... -
News On Track at CPHI Milan: Thermo Fisher Scientific Track Sponsor interview
With CPHI Milan just around the corner, we sat down with some of the sponsors for this year’s conference tracks to discuss the most pressing topics in pharma. -
News CPHI Milan Speaker Spotlight: Pharma Manufacturing and Localisation in Africa
In the run-up to CPHI Milan, we sit down with some of the experts and thought-leaders speaking at this year’s conferences. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Eli Lilly licenses rheumatoid arthritis manufacturing in Africa
American pharmaceutical company Eli Lilly has signed a partnership with Egyptian organisation Eva Pharma to localise manufacturing of rheumatoid arthritis treatments in Africa.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance